101 – 110 of 191
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
- Contribution to journal › Article
-
Mark
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
- Contribution to journal › Article
-
Mark
Comparing the Clinical Utility and Diagnostic Performance of Cerebrospinal Fluid P-Tau181, P-Tau217 and P-Tau231 Assays
- Contribution to journal › Article
-
Mark
Spatial Distribution of Tau and β-Amyloid Pathologies and Their Role in Different Alzheimer Disease Phenotypes
- Contribution to journal › Debate/Note/Editorial
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
- Contribution to journal › Article
-
Mark
Biomarker testing in MCI patients—deciding who to test
- Contribution to journal › Article
-
Mark
Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease
- Contribution to journal › Article
-
Mark
Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease
- Contribution to journal › Article
-
Mark
Associations of Plasma Phospho-Tau217 Levels with Tau Positron Emission Tomography in Early Alzheimer Disease
- Contribution to journal › Article
-
Mark
The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people
(2021) In Journals of Gerontology. Series A: Biological Sciences & Medical Sciences 76(4). p.683-691
- Contribution to journal › Article
